@CellFightMDi
iAccount based inUnited States!
About this account
- Account based in
- United States
- Connected via
- Web
! X says this location may be affected by a proxy or VPN.
Account-level information from X, not a live location or the device used for a specific post.
Fighting cancer with every cell. 🎗️
Manchester
Joined May 2023
- Tweets2.8K
- Following328
- Followers62
- Likes5.2K
Quantum nanosensors can see what organs-on-chips miss 👀🧬
Discover how integrating quantum sensing into microfluidic platforms could transform real-time, high-resolution biomedical monitoring.
Read more: azonano.com/news.aspx?newsID… #QuantumSensors #OrganOnAChip #Biotech
Dr. OncoGuru 🎗️ retweeted
Anyone doing this- prolonged balloon inflation during STEMI
“primary PCI assigned 1:1 to POP (stent inflation to ≥14 atm maintained until pressure stability, defined as no pressure drop ≥0.3 atm over 30 seconds) or conventional rapid inflation–deflation stenting”
#CardioX
Dr. OncoGuru 🎗️ retweeted
Adult T-cell Leukemia/Lymphoma - | ASH Image Bank | American Society of Hematology imagebank.hematology.org/ima… #ASHImageBank
Dr. OncoGuru 🎗️ retweeted
The evolving landscape of drug targets
nature.com/articles/s41573-0…
rdcu.be/22o1FPpNJ3Ga
In the past 25 years, advances in areas such as genomics and the diversification of therapeutic modalities have expanded the drug target landscape, which now includes ~700 targets mapped here
Dr. OncoGuru 🎗️ retweeted
Responses to ADC TUB-040 did not differ by NaPi2b expression level in platinum-resistant ovarian cancer, supporting a biomarker-unrestricted development path, according to Toon Van Gorp, MD, PhD. @ASCO #ASCO26 #gyncsm #oncology
More insights ➡️: onclive.com/view/napistar-1-…
Dr. OncoGuru 🎗️ retweeted
#WCLC26 Meet the Editors-in-Chief of #JTO @DrAlexAdjei and #JTOCRR Emily Stone
Thanks to those who stopped by and engaged in a great conversation or were simply there to listen and learn from the editors.
@IASLC @JTOonline @ElsevierConnect
Dr. OncoGuru 🎗️ retweeted
New paper out in @NatureMetabolism!
We show that loss of m⁶A disrupts pancreatic α-cell identity and promotes their transition toward immature β-cells.
My first as co-corresponding with lots of work from my new lab at @UChicago!
nature.com/articles/s42255-0…
Dr. OncoGuru 🎗️ retweeted
Now $13.5K shy of their target - so proud of this all-star #WoMMen team!!
Not too late to donate before the #IMS26 meeting in Glasgow - link 👇🏼, funds for myeloma research.
I spy #tanyawildes bracelets and will have to find the #downwithdex one she'd made for me... so cool!
The WoMMen of Myeloma are ready to hike the Scottish Highlands.
give.healthtree.org/campaign…
We are 14K shy of our target! So support us!
#MedTwitter #oncology #mmsm #hematolgy #research
Dr. OncoGuru 🎗️ retweeted
Replying to @AlhijjiM
@AlhijjiM with an amazing demonstration of treatment of cardiac masses percutaneously in icoach step by step session
@TCT_ME_ i've never seen such a demonstration in a meeting before
@mirvatalasnag @AlkashkariWail @drptca @kfaraidy @crfheart
Dr. OncoGuru 🎗️ retweeted
MRSA Decolonisation - First-Line Agents:
📍 Mupirocin 2% nasal ointment - first-line for nasal carriage - applied to both anterior nares twice daily x 5 days; inhibits bacterial isoleucyl-tRNA synthetase - protein synthesis blocked; anterior nares are the primary MRSA reservoir - eradicating nasal carriage is the cornerstone of decolonisation
📍 Chlorhexidine gluconate 4% body wash - daily whole-body wash x 5 days - reduces skin colonisation (axillae, groin, perineum); cationic biguanide - disrupts bacterial cell membrane; used in combination with mupirocin - nasal + skin decolonisation must be simultaneous to prevent re-colonisation from untreated sites
Alternatives when mupirocin resistance present:
📍 Nasal povidone-iodine 5-10% - broad antiseptic - no resistance development; increasingly used in surgical settings - single application before surgery comparable to 5-day mupirocin
📍 Retapamulin/Fusidic acid nasal - alternative topical agents where mupirocin resistance documented
Dr. OncoGuru 🎗️ retweeted
With expert CTO operator @ogoktekin just before the CTO case live in a box- he's the best @TCT_ME_ @mirvatalasnag @AlkashkariWail @drptca @kfaraidy @crfheart
Dr. OncoGuru 🎗️ retweeted
Replying to @aelsab
@aelsab with a superb case showing treatment of cardiac mass percutaneously. He has published the largest case series in endocarditis and is one of the foremost experts in the world in this arena @mirvatalasnag @AlkashkariWail @drptca @kfaraidy @crfheart
Dr. OncoGuru 🎗️ retweeted
There is no such thing as “too young for cancer.” I keep writing this because apparently some people still need to read it.
Our new @TheGutOncLab paper on early-onset cholangiocarcinoma is out, and the message is simple: Early-onset cancers aren't just a colorectal disease, and these patients are routinely ignored at diagnosis.
Sydney Towle helped early onset cholangiocarcinoma into the public eye via TikTok, but her experience with delayed diagnosis was sadly the norm.
Our data show the problem at scale.
We looked at >116,000 patients with cholangiocarcinoma, including >5,000 diagnosed before 50.
❌ Younger patients had 24% higher odds of waiting >30 days for a diagnosis
⌛️ Median diagnostic delay was two months
🙍♀️ Young women were particularly affected
The problem, as it seems, was getting to the diagnosis.
Early-age cancer is bigger than #EACRC.
One liner?
Young people get cancer too. When they tell us something is wrong, we should listen.
sciencedirect.com/science/ar…
Thanks for the opportunity to contribute @UGrewalMD
@Onco_Nexus @OncoAlert @OncoDailyGI
Dr. OncoGuru 🎗️ retweeted
Any lecture by Dr. Leung is a must-watch. Always insightful and thought-provoking!
@MayoClinicNeph @rc_oncneph @ShrutiGkidney @onconephsociety
If you work in onconephrology, Dr Nelson Leung is one of those names you keep coming back to.
Mayo nephrologist + hematologist, and founder/president of the International Kidney & Monoclonal Gammopathy Research Group.
@rc_oncneph @MayoClinicNeph
Dr. OncoGuru 🎗️ retweeted
Now online: Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial doi.org/10.1158/2326-6066.CI…
Dr. OncoGuru 🎗️ retweeted
What can we learn from children whose hepatoblastoma progresses or returns? At #SIOP2026, Allison O’Neill, MD, shares findings from the international RELIVE registry examining the presentation and outcomes of progressive and relapsed hepatoblastoma.
Dr. OncoGuru 🎗️ retweeted
PLEX and high-cutoff HD have given us a fascinating, and not entirely straightforward, story.
But the bigger shift is in myeloma therapy itself: can we shut down FLC production fast enough to rescue the kidney?
That feels like the more important question now.
Dr. OncoGuru 🎗️ retweeted
A new approach to chemotherapy-resistant ovarian cancer showed significant promise in a clinical trial that included an @OhioState research team.cancer.osu.edu/blog/new-ovar…